These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22306031)

  • 1. Motor neuron pathology and behavioral alterations at late stages in a SMA mouse model.
    Fulceri F; Bartalucci A; Paparelli S; Pasquali L; Biagioni F; Ferrucci M; Ruffoli R; Fornai F
    Brain Res; 2012 Mar; 1442():66-75. PubMed ID: 22306031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
    Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
    Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.
    Dominguez E; Marais T; Chatauret N; Benkhelifa-Ziyyat S; Duque S; Ravassard P; Carcenac R; Astord S; Pereira de Moura A; Voit T; Barkats M
    Hum Mol Genet; 2011 Feb; 20(4):681-93. PubMed ID: 21118896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a murine model of SMA.
    Donnelly EM; Quach ET; Hillery TM; Heeke BL; Snyder BR; Handy CR; O'Connor DM; Boulis NM; Federici T
    Neurobiol Dis; 2012 Mar; 45(3):992-8. PubMed ID: 22198571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Ighmbp2 in motor neurons and implications for the pathomechanism in a mouse model of human spinal muscular atrophy with respiratory distress type 1 (SMARD1).
    Grohmann K; Rossoll W; Kobsar I; Holtmann B; Jablonka S; Wessig C; Stoltenburg-Didinger G; Fischer U; Hübner C; Martini R; Sendtner M
    Hum Mol Genet; 2004 Sep; 13(18):2031-42. PubMed ID: 15269181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.
    El-Khodor BF; Edgar N; Chen A; Winberg ML; Joyce C; Brunner D; Suárez-Fariñas M; Heyes MP
    Exp Neurol; 2008 Jul; 212(1):29-43. PubMed ID: 18455159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy.
    Rindt H; Buckley DM; Vale SM; Krogman M; Rose FF; Garcia ML; Lorson CL
    Neuromuscul Disord; 2012 Mar; 22(3):277-85. PubMed ID: 22079083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciliary neurotrophic factor-induced sprouting preserves motor function in a mouse model of mild spinal muscular atrophy.
    Simon CM; Jablonka S; Ruiz R; Tabares L; Sendtner M
    Hum Mol Genet; 2010 Mar; 19(6):973-86. PubMed ID: 20022887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac defects contribute to the pathology of spinal muscular atrophy models.
    Shababi M; Habibi J; Yang HT; Vale SM; Sewell WA; Lorson CL
    Hum Mol Genet; 2010 Oct; 19(20):4059-71. PubMed ID: 20696672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurodevelopmental consequences of Smn depletion in a mouse model of spinal muscular atrophy.
    Liu H; Shafey D; Moores JN; Kothary R
    J Neurosci Res; 2010 Jan; 88(1):111-22. PubMed ID: 19642194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
    Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J
    J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
    Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
    PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
    Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
    Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoring Bcl-x(L) levels benefits a mouse model of spinal muscular atrophy.
    Tsai LK; Tsai MS; Ting CH; Wang SH; Li H
    Neurobiol Dis; 2008 Sep; 31(3):361-7. PubMed ID: 18590823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells.
    Boda B; Mas C; Giudicelli C; Nepote V; Guimiot F; Levacher B; Zvara A; Santha M; LeGall I; Simonneau M
    Eur J Hum Genet; 2004 Sep; 12(9):729-37. PubMed ID: 15162126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy.
    Harris AW; Butchbach ME
    Neuromuscul Disord; 2015 Sep; 25(9):699-705. PubMed ID: 26055638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
    Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
    Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation.
    Farooq F; Abadía-Molina F; MacKenzie D; Hadwen J; Shamim F; O'Reilly S; Holcik M; MacKenzie A
    Hum Mol Genet; 2013 Sep; 22(17):3415-24. PubMed ID: 23656793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease.
    Monani UR
    Neuron; 2005 Dec; 48(6):885-96. PubMed ID: 16364894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.